Baader Bank Aktiengesellschaft Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Baader Bank Aktiengesellschaft decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 866 shares of the biopharmaceutical company’s stock after selling 79 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Regeneron Pharmaceuticals were worth $617,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $37,000. Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $49,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.6 %

NASDAQ:REGN opened at $683.08 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $723.36 and a 200-day simple moving average of $928.61. Regeneron Pharmaceuticals, Inc. has a 52-week low of $666.25 and a 52-week high of $1,211.20. The company has a market capitalization of $75.06 billion, a PE ratio of 16.90, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10.

Wall Street Analyst Weigh In

Several analysts recently commented on REGN shares. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Sanford C. Bernstein decreased their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. Finally, Barclays lowered their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,004.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.